Decoy Therapeutics Inc. DCOY
0.87 USD -0.01 (-1.13%)
Regular-session close
0.87 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
0.8407 Day range 0.911
0.835 52-week range 16.92
- YTD
- -88.83%
- 1 year
- -90.77%
No chart data for this range yet.
- Market cap
- 2.08M
- EPS (ttm)
- 31.19
- P/E ratio
- 0.03
- YTD return
- -88.83%
- 1-year return
- -90.77%
- Volume
- 105.53K
- Avg volume
- 2.16M
- Open
- 0.852
- Previous close
- 0.88
- Day's range
- 0.8407 – 0.911
- 52-week range
- 0.835 – 16.92
Fundamental scorecard
6 of 25 checks passed on DCOY’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
DCOY Revenue — quarterly 307.43K
DCOY Net income — quarterly -2.99M
DCOY EPS — quarterly -3.53
News
Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards
Decoy Therapeutics Provides Third Quarter 2026 Business Update
Decoy Therapeutics to Present at The Small Cap Showcase
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Your note
Sign in to keep a note on DCOY — it syncs with the Stock Master app.
